|
Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class:
Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: vedolizumab |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA and EMA (2014)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9093 | vedolizumab |
| Synonyms |
| Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 300 |
| Other databases | |
| GtoPdb PubChem SID | 178104009 |
| PubChem SID | 178104009 |
| Search PubMed clinical trials | vedolizumab |
| Search PubMed titles | vedolizumab |
| Search PubMed titles/abstracts | vedolizumab |
| Wikipedia | Vedolizumab |
